<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title>PLoS ONE</journal-title><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">08-PONE-RA-07518R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0005158</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Immunology/Immune Response</subject><subject>Immunology/Immunity to Infections</subject><subject>Infectious Diseases/Bacterial Infections</subject><subject>Pathology/Immunology</subject></subj-group></article-categories><title-group><article-title>ESAT6-Induced IFN&#x003b3; and CXCL9 Can Differentiate Severity of Tuberculosis</article-title><alt-title alt-title-type="running-head">Chemokines in Tuberculosis</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hasan</surname><given-names>Zahra</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Jamil</surname><given-names>Bushra</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ashraf</surname><given-names>Mussarat</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Islam</surname><given-names>Muniba</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yusuf</surname><given-names>Muhammad S.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Khan</surname><given-names>Javaid A.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hussain</surname><given-names>Rabia</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Department of Pathology and Microbiology, The Aga Khan University, Karachi, Pakistan</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Department of Medicine, The Aga Khan University, Karachi, Pakistan</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Ojcius</surname><given-names>David M.</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">University of California Merced, United States of America</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>zahra.hasan@aku.edu</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: ZH. Performed the experiments: MA MI. Analyzed the data: ZH MA RH. Contributed reagents/materials/analysis tools: BJ MSY JAK. Wrote the paper: ZH RH.</p></fn></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>2</day><month>4</month><year>2009</year></pub-date><volume>4</volume><issue>4</issue><elocation-id>e5158</elocation-id><history><date date-type="received"><day>27</day><month>11</month><year>2008</year></date><date date-type="accepted"><day>6</day><month>3</month><year>2009</year></date></history><copyright-statement>Hasan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement><copyright-year>2009</copyright-year><abstract><sec><title>Background</title><p>Protective responses against <italic>Mycobacterium</italic> tuberculosis are dependent on appropriate T cell and macrophage activation. Mycobacterial antigen six kDa early secreted antigenic target (ESAT6) and culture filtrate protein 10 (CFP10) can detect <italic>M. tuberculosis</italic> specific IFN&#x003b3; responses. However, most studies have been performed in non-endemic regions and to study pulmonary tuberculosis (PTB). We have studied ESAT6 and CFP10 induced cytokine and chemokines responses in PTB and extrapulmonary (EPul) TB.</p></sec><sec sec-type="methods"><title>Methodology</title><p>IFN&#x003b3;, IL10, CXCL9 and CCL2 responses were determined using an <italic>ex vivo</italic> whole blood assay system in PTB (n&#x0200a;&#x0003d;&#x0200a;30) and EPulTB patients with limited (LNTB, n&#x0200a;&#x0003d;&#x0200a;24) or severe (SevTB, n&#x0200a;&#x0003d;&#x0200a;22) disease, and in healthy endemic controls (ECs). Responses to bacterial LPS were also determined.</p></sec><sec><title>Principal Findings</title><p>ESAT6- and CFP10-induced IFN&#x003b3; was comparable between ECs and TB patients. Both ESAT6- and CFP10-induced IFN&#x003b3; secretion was greater in LNTB than PTB. ESAT6-induced CXCL9 was greater in EPulTB as compared with PTB, with an increase in SevTB as compared with LNTB. CFP10-induced CCL2 was higher in PTB than LNTB patients. LPS-stimulated CXCL9 was greatest in SevTB and LPS-induced CCL2 was increased in PTB as compared with LNTB patients. A positive correlation between ESAT6-induced IFN&#x003b3; and CXCL9 was present in all TB patients, but IFN&#x003b3; and CCL2 was only correlated in LNTB. ESAT-induced CCL2 and CXCL9 were significantly associated in LNTB while correlation in response to LPS was only present in SevTB.</p></sec><sec><title>Conclusions</title><p>ESAT6 induced IFN&#x003b3; and CXCL9 can differentiate between limited and severe TB infections.</p></sec></abstract><counts><page-count count="8"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Protective immunity against <italic>Mycobacterium tuberculosis</italic> is dependent on the interplay between activated T cells, macrophages and other leucocytes, proinflammatory cytokines such as, interferon gamma (IFN&#x003b3;), tumor necrosis factor-alpha (TNF&#x003b1;) and interleukin (IL)-12, and down-modulatory cytokines IL-10 and transforming growth factor beta (TGF)-&#x003b2; <xref ref-type="bibr" rid="pone.0005158-BoneciniAlmeida1">&#x0005b;1&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005158-MendezSamperio1">&#x0005b;2&#x0005d;</xref>. IL10 produced by macrophages is important in regulating the Th1 cytokine balance and down regulates proinflammatory responses <xref ref-type="bibr" rid="pone.0005158-Murray1">&#x0005b;3&#x0005d;</xref>. TNF&#x003b1; regulated granuloma formation relies on effective recruitment of leucocytes, dependent on chemokines such as the CC chemokines; CCL2, CCL3, CCL4, CCL5 and CXC chemokines; CXCL8, CXCL9 and CXCL10 <xref ref-type="bibr" rid="pone.0005158-Collins1">&#x0005b;4&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005158-Flynn1">&#x0005b;7&#x0005d;</xref>. Coordinate expression of these chemokines with their receptors is essential for granuloma formation. Deficiency of the CCL2 receptor, CCR2, has been shown to result in progressive infection by <italic>M. tuberculosis</italic> in mice <xref ref-type="bibr" rid="pone.0005158-Scott1">&#x0005b;8&#x0005d;</xref>. CXCL9 stimulates T lymphocytes <xref ref-type="bibr" rid="pone.0005158-Whiting1">&#x0005b;9&#x0005d;</xref> and has previously been shown to be a sensitive predictive marker for antigen-specific IFN&#x003b3; production and IFN&#x003b3; secreting cells <xref ref-type="bibr" rid="pone.0005158-Brice1">&#x0005b;10&#x0005d;</xref>.</p><p>Rapid diagnosis of tuberculosis (TB) infections is essential for early detection and control of disease. Six kDa early secreted antigenic target (ESAT6) and culture filtrate protein 10 (CFP10) are both encoded by the region of difference 1 (RD1) which is present in <italic>M. tuberculosis</italic> and <italic>M. bovis,</italic> but absent from <italic>M. bovis</italic> BCG and most environmental mycobacteria <xref ref-type="bibr" rid="pone.0005158-Berthet1">&#x0005b;11&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005158-Harboe1">&#x0005b;12&#x0005d;</xref>. ESAT6 is a immunodominant T cell-stimulatory antigen and is recognized by specific IFN&#x003b3;-secreting T cells present in greater numbers in patients with active disease as compared with those who are un-infected <xref ref-type="bibr" rid="pone.0005158-Ravn1">&#x0005b;13&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005158-Ulrichs2">&#x0005b;14&#x0005d;</xref>. Commercial tests employing IFN&#x003b3; release assays (IGRA) such as, ESAT6 Quantiferon TB-2G <xref ref-type="bibr" rid="pone.0005158-Kobashi1">&#x0005b;15&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005158-Britton1">&#x0005b;16&#x0005d;</xref> and T-SPOT TB are increasingly available as diagnostic and predictive tests for vaccination. Therefore, ESAT6 and CFP10 induced IFN&#x003b3; responses have been shown to be useful in discriminating infected individuals from healthy controls <xref ref-type="bibr" rid="pone.0005158-Abramo1">&#x0005b;17&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005158-Ulrichs3">&#x0005b;19&#x0005d;</xref>. However, there are controversial reports from endemic regions. In TB endemic regions, IFN&#x003b3; can be modulated by natural exposure to <italic>M. tuberculosis</italic> or non-tuberculous mycobacteria as well as BCG vaccination <xref ref-type="bibr" rid="pone.0005158-Weir1">&#x0005b;20&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005158-Black1">&#x0005b;21&#x0005d;</xref>. Recent studies have shown that the sensitivity of IGRA may be related to the ethnic origin and age of the individual tested <xref ref-type="bibr" rid="pone.0005158-Chee1">&#x0005b;22&#x0005d;</xref>. The sensitivity of ESAT6 and CFP10 induced <italic>Mycobacterium</italic>-specific T cell responses is greatest in a BCG unvaccinated population in a non-endemic region and most studies have been performed in areas of low tuberculosis (TB) transmission <xref ref-type="bibr" rid="pone.0005158-Mazurek1">&#x0005b;23&#x0005d;</xref>, with less data available from high transmission TB endemic regions <xref ref-type="bibr" rid="pone.0005158-Demissie1">&#x0005b;24&#x0005d;</xref>. A recent study has shown that the utility of using additional biomarkers such as CCL2 and CXCL10 together with IFN&#x003b3; to assess mycobacterial antigen induced responses in identifying patients with <italic>M. tuberculosis</italic> infection <xref ref-type="bibr" rid="pone.0005158-Ruhwald1">&#x0005b;25&#x0005d;</xref>. However, most research has been performed on patients with pulmonary tuberculosis (PTB). Although PTB is the predominant form of tuberculosis, extra-pulmonary disease (EPulTB) involving; lymph nodes, skeletal system, abdomen, meningeal, miliary or disseminated forms of the disease remain common <xref ref-type="bibr" rid="pone.0005158-Cagatay1">&#x0005b;26&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005158-Ebdrup1">&#x0005b;27&#x0005d;</xref>. EPulTB presents an additional burden due to the problems associated with diagnosis and treatment of infections in extra-pulmonary sites. It is therefore essential to assess IFN&#x003b3; induced responses to mycobacterial antigens in endemic areas and in patients with PTB and EPulTB. This work has been carried out in Pakistan which is ranked 8<sup>th</sup> amongst high TB burden countries and has an incidence of 181/100,000 cases/year, where 44&#x00025; pulmonary and 15&#x00025; extrapulmonary samples are listed under new case detection for DOTS <xref ref-type="bibr" rid="pone.0005158-WHO1">&#x0005b;28&#x0005d;</xref>.</p><p>The <italic>ex vivo</italic> whole blood assay model is useful in assessing host immune responses in tuberculosis patients <xref ref-type="bibr" rid="pone.0005158-Hussain1">&#x0005b;29&#x0005d;</xref><xref ref-type="bibr" rid="pone.0005158-Hasan1">&#x0005b;30&#x0005d;</xref>, despite its limitations in identifying the cellular sources of secreted products. We have investigated mycobacterium specific responses using antigens ESAT6 and CFP10 and also response to bacterial lipopolysaccharide (LPS) in whole blood cultures of patients with PTB (n&#x0200a;&#x0003d;&#x0200a;30) and EPulTB (n&#x0200a;&#x0003d;&#x0200a;46) with differing disease severity. Cytokines (IFN&#x003b3; and IL10) and chemokines (CXCL9 and CCL2) were measured in each donor. Our results indicate that ESAT6-induced IFN&#x003b3; and CXCL9 responses do not discriminate between active TB patients and healthy endemic controls (ECs), but that they do differentiate severity of infections.</p></sec><sec id="s2"><title>Results</title><sec id="s2a"><title>Characteristics of study group</title><p><xref ref-type="table" rid="pone-0005158-t001">Table 1</xref> illustrates hematological characteristics of patients in the study. EPulTB patients were divided according to WHO ranking of severity into less severe TB (LNTB) or severe TB (SevTB) <xref ref-type="bibr" rid="pone.0005158-WHO1">&#x0005b;28&#x0005d;</xref>, see <xref ref-type="sec" rid="s4">methods</xref> and <xref ref-type="table" rid="pone-0005158-t002">Table 2</xref>. The study groups were comparable with respect to age and gender. As expected <xref ref-type="bibr" rid="pone.0005158-Ebdrup1">&#x0005b;27&#x0005d;</xref>, erythrocyte sedimentation rate (ESR) was found to be raised in TB patients as compared with ECs; PTB, LNTB and SevTB (p&#x0003c;0.01, 0.01, 0.01, respectively). Total leucocyte (TLC) and monocyte counts were comparable between patients and controls. However, in PTB and SevTB, lymphocyte counts were decreased (p&#x0200a;&#x0003d;&#x0200a;0.002, p&#x0003c;0.01, respectively), while neutrophil counts were increased (p&#x0200a;&#x0003d;&#x0200a;0.02, p&#x0200a;&#x0003d;&#x0200a;0.008, respectively).</p><table-wrap id="pone-0005158-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005158.t001</object-id><label>Table 1</label><caption><title>Characteristics of tuberculosis patients and healthy endemic controls.</title></caption><graphic id="pone-0005158-t001-1" xlink:href="pone.0005158.t001"/><table frame="hsides" rules="groups" alternate-form-of="pone-0005158-t001-1"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Characteristic</td><td align="left" rowspan="1" colspan="1">EC</td><td align="left" rowspan="1" colspan="1">PTB</td><td align="left" rowspan="1" colspan="1">LNTB</td><td align="left" rowspan="1" colspan="1">SevTB</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Number</bold></td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1">22</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Age (y)</bold></td><td align="left" rowspan="1" colspan="1">27.5&#x000b1;5.9</td><td align="left" rowspan="1" colspan="1">27.8&#x000b1;12.2</td><td align="left" rowspan="1" colspan="1">33.2&#x000b1;12.4</td><td align="left" rowspan="1" colspan="1">36.68&#x000b1;18.7</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Male&#x02236;Female</bold></td><td align="left" rowspan="1" colspan="1">9 vs 8</td><td align="left" rowspan="1" colspan="1">11 vs 19</td><td align="left" rowspan="1" colspan="1">9 vs 15</td><td align="left" rowspan="1" colspan="1">10 vs 12</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>ESR (mm/h)</bold></td><td align="left" rowspan="1" colspan="1">5.4&#x000b1;2.9</td><td align="left" rowspan="1" colspan="1">54&#x000b1;37<xref ref-type="table-fn" rid="nt102">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">34.4&#x000b1;25.2<xref ref-type="table-fn" rid="nt102">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">45.4&#x000b1;33.8<xref ref-type="table-fn" rid="nt102">&#x0002a;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Hb (g/dL)</bold></td><td align="left" rowspan="1" colspan="1">13.6&#x000b1;1.1</td><td align="left" rowspan="1" colspan="1">11.8&#x000b1;1.8<xref ref-type="table-fn" rid="nt102">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">12.3&#x000b1;1.6<xref ref-type="table-fn" rid="nt102">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">12.2&#x000b1;1.5<xref ref-type="table-fn" rid="nt102">&#x0002a;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>TLC (10e<sup>9</sup>/L)</bold></td><td align="left" rowspan="1" colspan="1">7.4&#x000b1;1.6</td><td align="left" rowspan="1" colspan="1">9.4&#x000b1;5.1</td><td align="left" rowspan="1" colspan="1">7.7&#x000b1;2.3</td><td align="left" rowspan="1" colspan="1">8.1&#x000b1;2.8</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Lymphocytes (10e<sup>9</sup>/L)</bold></td><td align="left" rowspan="1" colspan="1">2.3&#x000b1;0.5</td><td align="left" rowspan="1" colspan="1">1.7&#x000b1;0.7<xref ref-type="table-fn" rid="nt102">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">2.0&#x000b1;0.7</td><td align="left" rowspan="1" colspan="1">1.3&#x000b1;0.4<xref ref-type="table-fn" rid="nt102">&#x0002a;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Monocytes (10e<sup>8</sup>/L)</bold></td><td align="left" rowspan="1" colspan="1">5.3&#x000b1;1.6</td><td align="left" rowspan="1" colspan="1">6.0&#x000b1;2.8</td><td align="left" rowspan="1" colspan="1">5.8&#x000b1;2.4</td><td align="left" rowspan="1" colspan="1">4.7&#x000b1;1.7</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Neutrophils (10e<sup>9</sup>/L)</bold></td><td align="left" rowspan="1" colspan="1">4.3&#x000b1;1.2</td><td align="left" rowspan="1" colspan="1">7.0&#x000b1;4.7<xref ref-type="table-fn" rid="nt102">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">5.0&#x000b1;2.0</td><td align="left" rowspan="1" colspan="1">6.0&#x000b1;2.7<xref ref-type="table-fn" rid="nt102">&#x0002a;</xref></td></tr></tbody></table><table-wrap-foot><fn id="nt101"><p>EC, healthy endemic controls; PTB, pulmonary TB; LNTB, limited extrapulmonary TB; SevTB, severe extrapulmonary TB.</p></fn><fn id="nt102"><label>&#x0002a;</label><p>denotes significant difference (p&#x0003c;0.05) as compared with EC.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone-0005158-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005158.t002</object-id><label>Table 2</label><caption><title>Diagnostic criteria for patients with severe extrapulmonary tuberculosis.</title></caption><graphic id="pone-0005158-t002-2" xlink:href="pone.0005158.t002"/><table frame="hsides" rules="groups" alternate-form-of="pone-0005158-t002-2"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">No.</td><td align="left" rowspan="1" colspan="1">Site of tuberculosis</td><td align="left" rowspan="1" colspan="1">Abscess</td><td align="left" rowspan="1" colspan="1">Microscopy<xref ref-type="table-fn" rid="nt103">a</xref></td><td align="left" rowspan="1" colspan="1">Radiology<xref ref-type="table-fn" rid="nt104">b</xref></td><td align="left" rowspan="1" colspan="1">AFBC<xref ref-type="table-fn" rid="nt105">c</xref></td><td align="left" rowspan="1" colspan="1">Histopathology<xref ref-type="table-fn" rid="nt106">d</xref></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">Spine</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Positive</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">Spine</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Negative</td><td align="left" rowspan="1" colspan="1">Positive</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">Spine</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">Spine</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">Positive</td></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">Spine</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">Spine</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">Spine</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">Spine</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Negative</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">Positive</td></tr><tr><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">Spine</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Positive</td></tr><tr><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">Meninges<xref ref-type="table-fn" rid="nt107">e</xref></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Negative</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">Meninges<xref ref-type="table-fn" rid="nt107">e</xref></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Negative</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">Meninges</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">Positive</td></tr><tr><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">Meninges</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">Meninges<xref ref-type="table-fn" rid="nt107">e</xref></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Negative</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Negative</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">Meninges<xref ref-type="table-fn" rid="nt107">e</xref></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Positive</td></tr><tr><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">Abdomen</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Positive</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Negative</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">Abdomen</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Negative</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Positive</td></tr><tr><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">Abdomen</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Negative</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">19</td><td align="left" rowspan="1" colspan="1">Miliary</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Negative</td><td align="left" rowspan="1" colspan="1">Positive</td></tr><tr><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">Intestines</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Positive</td></tr><tr><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">Bilateral Pleural</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Negative</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Negative</td><td align="left" rowspan="1" colspan="1">Positive</td></tr><tr><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">Bilateral Pleural</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="nt103"><label>a</label><p>indicates acid fast bacilli staining of smears.</p></fn><fn id="nt104"><label>b</label><p>includes Xray, MRI or CT imaging characteristic of tuberculosis.</p></fn><fn id="nt105"><label>c</label><p>acid fast bacilli culture using BACTEC radiometric assay, Becton Dickinson, USA.</p></fn><fn id="nt106"><label>d</label><p>biopsy results indicate caseating or necrotic granulomatous inflammation indicative of <italic>M. tuberculosis</italic> infection.</p></fn><fn id="nt107"><label>e</label><p>showed a favorable clinical response to anti-tuberculous treatment.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2b"><title>Cytokine and chemokine secretion in unstimulated whole blood cultures of TB patients and endemic controls</title><p>IFN&#x003b3;, IL10 and CXCL9 and CCL2 secretion from unstimulated cells was measured in healthy endemic controls (ECs, n&#x0200a;&#x0003d;&#x0200a;17) and in TB patients (n&#x0200a;&#x0003d;&#x0200a;76, <xref ref-type="table" rid="pone-0005158-t003">Table 3</xref>). IFN&#x003b3;, IL10 and CCL2 secretion from unstimulated whole blood cells of ECs and TB patients were comparable. However, CXCL9 secretion from unstimulated whole blood cells of ECs was greater than in TB patients (p&#x0200a;&#x0003d;&#x0200a;0.031).</p><table-wrap id="pone-0005158-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005158.t003</object-id><label>Table 3</label><caption><title>ESAT6- and CFP10-induced cytokine and chemokine responses.</title></caption><graphic id="pone-0005158-t003-3" xlink:href="pone.0005158.t003"/><table frame="hsides" rules="groups" alternate-form-of="pone-0005158-t003-3"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><tbody><tr><td colspan="5" align="left" rowspan="1"><bold>Unstimulated cells</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Group (n)</td><td align="left" rowspan="1" colspan="1">IFN&#x003b3; (Mean&#x000b1;SD pg/ml)</td><td align="left" rowspan="1" colspan="1">IL10 (Mean&#x000b1;SD (pg/ml)</td><td align="left" rowspan="1" colspan="1">CXCL9 (Mean&#x000b1;SD pg/ml)</td><td align="left" rowspan="1" colspan="1">CCL2 (Mean&#x000b1;SD pg/ml)</td></tr><tr><td align="left" rowspan="1" colspan="1">EC (17)</td><td align="left" rowspan="1" colspan="1">2.0&#x000b1;2.8</td><td align="left" rowspan="1" colspan="1">136.8&#x000b1;287</td><td align="left" rowspan="1" colspan="1">7.9&#x000b1;20.2</td><td align="left" rowspan="1" colspan="1">86&#x000b1;327</td></tr><tr><td align="left" rowspan="1" colspan="1">TB (76)</td><td align="left" rowspan="1" colspan="1">6.3&#x000b1;13</td><td align="left" rowspan="1" colspan="1">10.8&#x000b1;17.9</td><td align="left" rowspan="1" colspan="1">2.3&#x000b1;18.8<xref ref-type="table-fn" rid="nt110">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">90.4&#x000b1;334</td></tr><tr><td colspan="5" align="left" rowspan="1"><bold>ESAT6-induced responses</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Group (n)</td><td align="left" rowspan="1" colspan="1">&#x003b4;IFN&#x003b3; (Mean&#x000b1;SD pg/ml)</td><td align="left" rowspan="1" colspan="1">&#x003b4;IL10 (Mean&#x000b1;SD (pg/ml)</td><td align="left" rowspan="1" colspan="1">&#x003b4;CXCL9 (Mean&#x000b1;SD pg/ml)</td><td align="left" rowspan="1" colspan="1">&#x003b4;CCL2 (Mean&#x000b1;SD pg/ml)</td></tr><tr><td align="left" rowspan="1" colspan="1">EC (17)</td><td align="left" rowspan="1" colspan="1">29&#x000b1;46</td><td align="left" rowspan="1" colspan="1">12&#x000b1;36</td><td align="left" rowspan="1" colspan="1">1.7&#x000b1;6.5</td><td align="left" rowspan="1" colspan="1">1456&#x000b1;1300</td></tr><tr><td align="left" rowspan="1" colspan="1">TB (76)</td><td align="left" rowspan="1" colspan="1">299&#x000b1;520</td><td align="left" rowspan="1" colspan="1">93&#x000b1;225</td><td align="left" rowspan="1" colspan="1">123&#x000b1;278<xref ref-type="table-fn" rid="nt110">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">1197&#x000b1;843</td></tr><tr><td colspan="5" align="left" rowspan="1"><bold>CFP-induced responses</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Group (n)</td><td align="left" rowspan="1" colspan="1">&#x003b4;IFN&#x003b3; (Mean&#x000b1;SD pg/ml)</td><td align="left" rowspan="1" colspan="1">&#x003b4;IL10 (Mean&#x000b1;SD (pg/ml)</td><td align="left" rowspan="1" colspan="1">&#x003b4;CXCL9 (Mean&#x000b1;SD pg/ml)</td><td align="left" rowspan="1" colspan="1">&#x003b4;CCL2 (Mean&#x000b1;SD pg/ml</td></tr><tr><td align="left" rowspan="1" colspan="1">EC (17)</td><td align="left" rowspan="1" colspan="1">286&#x000b1;442</td><td align="left" rowspan="1" colspan="1">23.4&#x000b1;70.2</td><td align="left" rowspan="1" colspan="1">19.6&#x000b1;31.9</td><td align="left" rowspan="1" colspan="1">2787&#x000b1;2293</td></tr><tr><td align="left" rowspan="1" colspan="1">TB (64)</td><td align="left" rowspan="1" colspan="1">635&#x000b1;720</td><td align="left" rowspan="1" colspan="1">155&#x000b1;237<xref ref-type="table-fn" rid="nt110">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">792&#x000b1;1113<xref ref-type="table-fn" rid="nt110">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">2076&#x000b1;1149</td></tr><tr><td colspan="5" align="left" rowspan="1"><bold>LPS-induced responses</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Group (n)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x003b4;IL10 (Mean&#x000b1;SD (pg/ml)</td><td align="left" rowspan="1" colspan="1">&#x003b4;CXCL9 (Mean&#x000b1;SD pg/ml)</td><td align="left" rowspan="1" colspan="1">&#x003b4;CCL2 (Mean&#x000b1;SD pg/ml</td></tr><tr><td align="left" rowspan="1" colspan="1">EC (17)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">342&#x000b1;577</td><td align="left" rowspan="1" colspan="1">17.3&#x000b1;46</td><td align="left" rowspan="1" colspan="1">3536&#x000b1;1504</td></tr><tr><td align="left" rowspan="1" colspan="1">TB (64)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">614.4&#x000b1;733</td><td align="left" rowspan="1" colspan="1">390&#x000b1;979<xref ref-type="table-fn" rid="nt110">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">1920&#x000b1;1047<xref ref-type="table-fn" rid="nt110">&#x0002a;</xref></td></tr></tbody></table><table-wrap-foot><fn id="nt108"><p>EC, healthy endemic controls; TB, tuberculosis patients.</p></fn><fn id="nt109"><p>&#x02018;&#x003b4;&#x02019; denotes cytokine secretion after background subtraction in each case.</p></fn><fn id="nt110"><label>&#x0002a;</label><p>denotes significant difference (p&#x0003c;0.05) as compared with EC.</p></fn><fn id="nt111"><p>All statistical analyses performed using the Mann-Whitney U non-parametric test.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2c"><title>Mycobacterial antigens ESAT6-induced IFN&#x003b3;, IL10, CCL2 and CXCL9 in TB patients</title><p>ESAT6&#x02013;induced cytokine and chemokines responses were determined in whole blood cells of 76 TB patients. Upon stimulation by ESAT6, the trend of IFN&#x003b3; secretion at 5 day post-stimulation was greater in TB patients as compared with ECs but did not achieve statistical significance (<xref ref-type="table" rid="pone-0005158-t003">Table 3</xref>). ESAT6-induced IL10 secretion was also increased in TB patients but was not statistically significant as compared with ECs (p&#x0200a;&#x0003d;&#x0200a;0.07).</p><p>CXCL9 has been shown to be induced by ESAT6 in patients with pulmonary TB <xref ref-type="bibr" rid="pone.0005158-Abramo1">&#x0005b;17&#x0005d;</xref>. We found ESAT6-induced CXCL9 to be significantly greater in TB patients as compared with ECs (p&#x0200a;&#x0003d;&#x0200a;0.003). While, no difference was observed between ESAT6-induced CCL2 in TB patients and ECs.</p></sec><sec id="s2d"><title>CFP-10 induced cytokine and chemokine responses</title><p>We also compared CFP10 induced whole blood cell responses in ECs and TB patients. CFP10-induced IFN&#x003b3; was increased in TB as compared with ECs but was not significantly different (<xref ref-type="table" rid="pone-0005158-t003">Table 3</xref>). CFP10-induced IL10 (p&#x0200a;&#x0003d;&#x0200a;0.002) secretion and also CXCL9 (p&#x0200a;&#x0003d;&#x0200a;0.001) secretion was significantly raised in TB patients. However, there was no difference in CFP10-induced CCL2 between patients and controls. Although the trend of responses to ESAT6 and CFP10 were comparable, the magnitude of cytokine responses to CFP10 was approximately 2 fold greater than that induced by ESAT6.</p></sec><sec id="s2e"><title>LPS-induced cytokine and chemokine secretion in TB patients</title><p>To investigate whether the differences in cytokine secretion observed were specific to mycobacterial antigens, we also studied cytokine and chemokine responses to bacterial lipopolysaccharide (LPS), a strong activator of macrophages. LPS-induced IL10 was not different between TB patients and ECs, <xref ref-type="table" rid="pone-0005158-t003">Table 3</xref>. However, LPS-induced CXCL9 was significantly greater (p&#x0200a;&#x0003d;&#x0200a;0.008), while CCL2 was reduced (p&#x0003c;0.01) in TB patients as compared with ECs.</p></sec><sec id="s2f"><title>Differential ESAT6-induced IFN&#x003b3; in pulmonary and extrapulmonary TB</title><p>We further investigated IFN&#x003b3; responses to mycobacterial antigens in TB patients with pulmonary and extrapulmonary disease of differing severity. Pulmonary TB patients included in the study comprised those with minimal (n&#x0200a;&#x0003d;&#x0200a;6) and moderate (n&#x0200a;&#x0003d;&#x0200a;24) disease. However, we found antigen stimulated IFN&#x003b3; secretion in minimal and moderate PTB patients to be comparable between groups (data not shown) and have therefore performed further analysis on the combined minimal/ moderate PTB group.</p><p>Responses in PTB patients were compared with those of EPul-TB; limited (LNTB) or severe (SevTB). As illustrated in <xref ref-type="fig" rid="pone-0005158-g001">Fig. 1A</xref>, ESAT6-induced IFN&#x003b3; in LNTB (median, 253 pg/ml) was significantly greater than in PTB (median, 3 pg/ml, p&#x0200a;&#x0003d;&#x0200a;0.011). IFN&#x003b3; responses in LNTB were significantly greater as compared with SevTB (median, 1 pg/ml, p&#x0200a;&#x0003d;&#x0200a;0.029). ESAT6-induced IL10 was negligible in all TB groups (PTB, LNTB, SevTB; 0, 3, 3 pg/ml respectively, data not shown).</p><fig id="pone-0005158-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005158.g001</object-id><label>Figure 1</label><caption><title>Differential ESAT6-induced IFN&#x003b3; and CXCL9 in pulmonary and extrapulmonary TB.</title><p>Whole blood cells were stimulated with ESAT6 at 5 &#x000b5;g/ml, and IFN&#x003b3; measured in cell supernatants harvested at 5 day post-stimulation, while CXCL9 was measured at 2 days post-stimulation. TB patient groups comprised those with pulmonary TB (PTB, n&#x0200a;&#x0003d;&#x0200a;30), less severe EPulTB (LNTB, n&#x0200a;&#x0003d;&#x0200a;24) and severe EPulTB (SevTB, n&#x0200a;&#x0003d;&#x0200a;22). The box plots represent data from each group after cytokine secretion from unstimulated cells has been subtracted. The whiskers indicate the 25<sup>th</sup> and 75<sup>th</sup> quartile respectively, while the median line separates the two. &#x02018;&#x0002a;&#x02019; denotes significant differences between groups, p&#x0003c;0.05; (&#x0002a;). A. IFN&#x003b3;, B. CXCL9.</p></caption><graphic xlink:href="pone.0005158.g001"/></fig><p>The balance between proinflammatory IFN&#x003b3; and downmodulatory IL10 has been shown to be critical in determining outcome of mycobacterial infections <xref ref-type="bibr" rid="pone.0005158-Hussain2">&#x0005b;31&#x0005d;</xref>, and the IFN&#x003b3; (5d) /IL10 (2d) ratio induced in response to mycobacterial antigens has been shown to be to be an indicator of disease severity in tuberculosis <xref ref-type="bibr" rid="pone.0005158-Jamil1">&#x0005b;32&#x0005d;</xref>. We found the ESAT6-induced IFN&#x003b3;/IL10 ratio to be significantly greater in LNTB (median, 3.5) as compared with the SevTB group (median, 1; p&#x0200a;&#x0003d;&#x0200a;0.011, data not shown), consistent with these earlier reports.</p><p>ESAT6-induced CXCL9 was significantly raised in EPulTB groups SevTB (p&#x0003c;0.01) and LNTB (p&#x0200a;&#x0003d;&#x0200a;0.029) as compared with PTB (<xref ref-type="fig" rid="pone-0005158-g001">Fig. 1B</xref>). No difference was observed between ESAT6-induced CCL2 in whole blood cells of PTB, LNTB or SevTB patients (median; 782, 1568 and 1056 pg/ml, respectively, data not shown).</p></sec><sec id="s2g"><title>CFP10-induced cytokine and chemokine responses in PTB and EPulTB</title><p>CFP10-induced IFN&#x003b3; was greater in LNTB as compared with PTB patients (p&#x0200a;&#x0003d;&#x0200a;0.044), but did not differ from with SevTB, <xref ref-type="fig" rid="pone-0005158-g002">Fig. 2A</xref>. CFP10-induced IL10 was found to be comparable between the TB patient groups (median; PTB, 22; LNTB, 30; SevTB, 52 pg/ml, data not shown).</p><fig id="pone-0005158-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005158.g002</object-id><label>Figure 2</label><caption><title>Differential CFP10-induced IFN&#x003b3; and CCL2 in PTB and EPulTB.</title><p>Whole blood cells from different patients were stimulated with CFP10 at 5 &#x000b5;g/ml. IFN&#x003b3; and CCL2 were measured in cell supernatants. All other parameters as described in <xref ref-type="fig" rid="pone-0005158-g001">Fig. 1</xref>. The box plots indicate cytokine secretion in PTB, LNTB and SevTB groups. A. IFN&#x003b3;, B. CCL2.</p></caption><graphic xlink:href="pone.0005158.g002"/></fig><p>Coincident with results observed in response to ESAT6, CFP10-induced IFN&#x003b3; /IL10 ratio was also greater in LNTB patients (median, 35) as compared with those with SevTB (median, 0.1; p&#x0200a;&#x0003d;&#x0200a;0.001, data not shown).</p><p>No differences were observed in CFP10-induced CXCL9 in PTB (51 pg/ml) and EPulTB groups, although CFP10 induced a greater trend of CXCL9 secretion in LNTB and SevTB (543, 192 pg/ml, respectively, data not shown). As observed in the case of IFN&#x003b3;, CFP10-induced CXCL9 was 2 fold greater in magnitude as compared with that in response to ESAT6.</p><p>However, CFP10-induced a significantly greater CCL2 response in PTB patients as compared with LNTB (p&#x0200a;&#x0003d;&#x0200a;0.036, <xref ref-type="fig" rid="pone-0005158-g002">Fig. 2B</xref>).</p></sec><sec id="s2h"><title>LPS-induced CXCL9 and CCL2 is greater in severe as compared with limited TB</title><p>When LPS-induced CXCL9 was measured in PTB, LNTB and SevTB groups it was observed that chemokine levels were significantly greater in SevTB as compared with PTB and LNTB (p&#x0200a;&#x0003d;&#x0200a;0.001, 0.004, respectively), <xref ref-type="fig" rid="pone-0005158-g003">Fig. 3A</xref>. In contrast, LPS-induced CCL2 was greater in PTB as compared with LNTB (p&#x0200a;&#x0003d;&#x0200a;0.01) and also in SevTB patients as compared with LNTB (p&#x0200a;&#x0003d;&#x0200a;0.003), <xref ref-type="fig" rid="pone-0005158-g003">Fig. 3B</xref>.</p><fig id="pone-0005158-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005158.g003</object-id><label>Figure 3</label><caption><title>Differential LPS-induced CXCL9 and CCL2 in limited and severe TB.</title><p>Whole blood cells were stimulated with LPS at 1 &#x000b5;g/ml and CXCL9 measured in cell supernatants harvested at 2 days post-stimulation. All other parameters as described in <xref ref-type="fig" rid="pone-0005158-g001">Fig. 1</xref>. A. CXCL9 and B. CCL2.</p></caption><graphic xlink:href="pone.0005158.g003"/></fig></sec><sec id="s2i"><title>Relationship between CXCL9, CCL2 and IFN&#x003b3; secretion in tuberculosis patients</title><p>We next determined the association between cytokine and chemokine responses induced to mycobacterial antigen ESAT6 and to LPS in different TB patient groups. A Spearman's rank correlation analysis showed ESAT6-induced secretion of IFN&#x003b3; and CXCL9 to be positively associated in all TB groups (<xref ref-type="table" rid="pone-0005158-t004">Table 4</xref>). A significant association between ESAT6-induced IFN&#x003b3; and CCL2 (R&#x0200a;&#x0003d;&#x0200a;0.471, p&#x0200a;&#x0003d;&#x0200a;0.027) and between CCL2 and CXCL9 (R&#x0200a;&#x0003d;&#x0200a;0.57, p&#x0200a;&#x0003d;&#x0200a;0.006) was observed only in the LNTB group, data not shown.</p><table-wrap id="pone-0005158-t004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005158.t004</object-id><label>Table 4</label><caption><title>Correlation between cytokines and chemokines stimulated by ESAT6 and LPS.</title></caption><graphic id="pone-0005158-t004-4" xlink:href="pone.0005158.t004"/><table frame="hsides" rules="groups" alternate-form-of="pone-0005158-t004-4"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="3" align="left" rowspan="1">IFN&#x003b3; to CXCL9</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td colspan="3" align="left" rowspan="1">TB group</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><bold>PTB</bold></td><td align="left" rowspan="1" colspan="1"><bold>LNTB</bold></td><td align="left" rowspan="1" colspan="1"><bold>SevTB</bold></td></tr></thead><tbody><tr><td colspan="4" align="left" rowspan="1"><bold>ESAT6</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">R</td><td align="left" rowspan="1" colspan="1">0.583<xref ref-type="table-fn" rid="nt114">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">0.508<xref ref-type="table-fn" rid="nt114">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">0.577<xref ref-type="table-fn" rid="nt114">&#x0002a;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>p-value</italic></td><td align="left" rowspan="1" colspan="1"><italic>0.001</italic></td><td align="left" rowspan="1" colspan="1"><italic>0.016</italic></td><td align="left" rowspan="1" colspan="1"><italic>0.015</italic></td></tr></tbody></table><table frame="hsides" rules="groups" alternate-form-of="pone-0005158-t004-4"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="3" align="left" rowspan="1">CXCL9 to CCL2</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td colspan="3" align="left" rowspan="1">TB group</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><bold>PTB</bold></td><td align="left" rowspan="1" colspan="1"><bold>LNTB</bold></td><td align="left" rowspan="1" colspan="1"><bold>SevTB</bold></td></tr></thead><tbody><tr><td colspan="4" align="left" rowspan="1"><bold>LPS</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">R</td><td align="left" rowspan="1" colspan="1">&#x02212;0.073</td><td align="left" rowspan="1" colspan="1">0.16</td><td align="left" rowspan="1" colspan="1">0.689<xref ref-type="table-fn" rid="nt115">&#x0002a;&#x0002a;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>p-value</italic></td><td align="left" rowspan="1" colspan="1"><italic>0.789</italic></td><td align="left" rowspan="1" colspan="1"><italic>0.569</italic></td><td align="left" rowspan="1" colspan="1"><italic>0.006</italic></td></tr></tbody></table><table-wrap-foot><fn id="nt112"><p>EC, endemic controls; PTB, pulmonary TB; LNTB, less severe EPul-TB; SevTB, severe EPul-TB.</p></fn><fn id="nt113"><p>R values 0.4&#x02013;0.6 indicate a moderate positive association.</p></fn><fn id="nt114"><label>&#x0002a;</label><p>while 0.6&#x02013;0.8 indicate a strong positive association</p></fn><fn id="nt115"><label>&#x0002a;&#x0002a;</label><p>p value&#x02264;0.05 are significantly different.</p></fn></table-wrap-foot></table-wrap><p>No association was found between LPS-induced IL10 and either CXCL9 or CCL2. However, LPS-induced CXCL9 and CCL2 were found to be positively associated in patients with SevTB but not in PTB or LNTB groups (<xref ref-type="table" rid="pone-0005158-t004">Table 4</xref>).</p></sec></sec><sec id="s3"><title>Discussion</title><p>The relationship between cytokines, IFN&#x003b3; and IL10 in regulating the outcome of <italic>M. tuberculosis</italic> infections is well studied. We have recently shown that circulating levels of IFN&#x003b3; and CXCL9 differ in patients with pulmonary and extrapulmonary disease <xref ref-type="bibr" rid="pone.0005158-Hasan2">&#x0005b;33&#x0005d;</xref>. We show here that the relationship between mycobacterial antigen induced IFN&#x003b3; and CXCL9 may play a role in determining disease severity in tuberculosis.</p><p>Our study illustrates that in a TB endemic region, ESAT6-induced IFN&#x003b3; responses may not be as effective in distinguishing patients with active disease from healthy individuals in endemic regions. This may be attributed to immune modulation of IFN&#x003b3; responses to specific <italic>M. tuberculosis</italic> antigens as has been shown in a recent study of household contacts of TB patients <xref ref-type="bibr" rid="pone.0005158-Hussain2">&#x0005b;31&#x0005d;</xref>. Also, a high rate of transmission in endemic regions may result in modulation of IFN&#x003b3; and IL10 responses due to increased exposure to environmental mycobacteria <xref ref-type="bibr" rid="pone.0005158-Black1">&#x0005b;21&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005158-Weir2">&#x0005b;34&#x0005d;</xref>.</p><p>Amongst healthy controls we studied asymptomatic individuals who were both TST&#x02212; and TST&#x0002b;. However, we did not observe any difference between cytokine or chemokine induced responses from whole blood cells of either group either after measurement from unstimulated cells or from ESAT6 or CFP10 stimulated cells (data not shown), corresponding with previous reports <xref ref-type="bibr" rid="pone.0005158-Hasan3">&#x0005b;35&#x0005d;</xref>. However, when both EC groups; TST&#x02212; and TST&#x0002b; donors were compared with TB patients, a significant differences in ESAT6- and CFP10-induced CXCL9 and CCL2 secretion was found in TB patients as compared with TST&#x02212; individuals but not in the TST&#x0002b; group (data not shown). This may be attributed to latent infection in the TST&#x0002b; controls which would raise specific cytokine responses to mycobacterial antigens. Previous reports have shown Th1-like effector memory cells to be increased in bronchoalveolar cells from TST&#x0002b; individuals as compared with TST&#x02212; individuals, with coordinate increase in IFN&#x003b3; and IFN&#x003b3; regulated chemokines <xref ref-type="bibr" rid="pone.0005158-Walrath1">&#x0005b;36&#x0005d;</xref>. Therefore, in our study we have compared responses of TB patients with Ecs who are TST&#x02212; in order to have the least exposed group as a control.</p><p>In all cases, antigen-induced IFN&#x003b3; secretion increased in magnitude from 2 to 5 days post-stimulation (data not shown). This may be attributed to the differing cellular sources of IFN&#x003b3; whereby at the earlier time point there would be a greater contribution from effector T cells, NK cells, &#x003b3;&#x003b4; T cells and activated macrophages, while at the latter time point the IFN&#x003b3; may primarily be released from mycobacterium specific T memory cells.</p><p>We found ESAT6-induced IFN&#x003b3; response to be decreased in patients with severe disseminated TB, comprising of those with spinal, meningeal, abdominal, miliary involvement, as compared with localised disease. Tuberculous lymphadenitis is the most common presentation of extrapulmonary TB. It is often a self-limiting disease and is less severe as compared with other forms. Increased IFN&#x003b3; responses in less severe TB infections correlates with previous work which has shown the frequency of antigen specific CD4 T cells to be greater in latently infected individuals and in those with minimal disease with a low bacterial burden as compared with patients with a higher bacterial load <xref ref-type="bibr" rid="pone.0005158-Pathan1">&#x0005b;37&#x0005d;</xref>. Therefore, patients with limited extrapulmonary disease may be more likely to have an increased number of IFN&#x003b3; secreting T cells as compared with those with progressive disease <xref ref-type="bibr" rid="pone.0005158-Pathan1">&#x0005b;37&#x0005d;</xref>. Previous reports haves shown that in pulmonary TB, there is a decrease in IFN&#x003b3; responses related to increased severity of disease <xref ref-type="bibr" rid="pone.0005158-Dlugovitzky1">&#x0005b;38&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005158-Sharma1">&#x0005b;39&#x0005d;</xref>.</p><p>Our data corresponds with previous work which has shown that differences in the severity of extrapulmonary TB can be defined by the IFN&#x003b3;: IL10 ratio to mycobacterial antigens, with a direct relationship between disseminated disease or disease localized to peripheral sites without lung involvement <xref ref-type="bibr" rid="pone.0005158-Jamil1">&#x0005b;32&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005158-Sahiratmadja1">&#x0005b;40&#x0005d;</xref>.</p><p>CXCL9 is IFN&#x003b3; induced and has been shown to be an early marker of IFN&#x003b3; activation and of T cells secreting IFN&#x003b3; <xref ref-type="bibr" rid="pone.0005158-Brice1">&#x0005b;10&#x0005d;</xref>. CXCL9 is a chemotactic ligand produced by macrophages and other antigen presenting cells at the site of inflammation <xref ref-type="bibr" rid="pone.0005158-Whiting1">&#x0005b;9&#x0005d;</xref>. We found ESAT6-induced CXCL9 to be increased in TB patients, corresponding with previous reports <xref ref-type="bibr" rid="pone.0005158-Abramo1">&#x0005b;17&#x0005d;</xref>. This corresponds with reports by Gonzalez-Juarrero <italic>et</italic> al. who show upregulated expression of IFN&#x003b3; regulated chemokines transcripts in response to <italic>M. tuberculosis</italic> coordinate with inflammation in the mouse model <xref ref-type="bibr" rid="pone.0005158-GonzalezJuarrero1">&#x0005b;41&#x0005d;</xref>. The increase in CXCL9 observed in severe extrapulmonary disease corresponds with literature which have shown chemokines responses to be increased in severe TB such as in tuberculous meningitis <xref ref-type="bibr" rid="pone.0005158-Mastroianni1">&#x0005b;42&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005158-Thwaites1">&#x0005b;43&#x0005d;</xref>. CFP10-induced activation of CXCL9 was greater than that observed for ESAT6 just as observed in the case of IFN&#x003b3;. Although the trend of responses to ESAT6 and CFP10 was comparable, ESAT6 appeared to elicit more significant difference in responses between limited and severe TB. This may be due to differential recognition of cell surface receptors for the recombinant antigens on T cells which may determine the magnitude of IFN&#x003b3; response and subsequently impact macrophage activation.</p><p>ESAT6 stimulated secretion of induced- CCL2 was not different between TB groups, further indicating the utility of this antigen in eliciting T cell specific responses.</p><p>LPS is a strong stimulant of monocyte responses, and both CXCL9 and CCL2 are produced by monocytes. Raised LPS-induced CXCL9 in severe extrapulmonary TB may be indicative of the increased inflammatory processes ongoing in progressive, disseminated disease and an absence of regulation. CCL2 has previously been shown to be increased in PTB patients as compared with Epul-TB patients and our results with LPS support this. In addition, we observe that as in case with CXCL9, CCL2 levels are raised in severe TB as compared with limited disease in patients with extrapulmonary TB.</p><p>Our correlation analysis between the cytokines and chemokines produced by whole blood cells of TB patients indicates differential regulation of cytokines in response to mycobacterial antigen stimulation in patients with differing disease severity. A positive association was found between ESAT6 induced IFN&#x003b3; and CXCL9 in all TB patients indicating that this balance may play a predictive role in the Th1-like cytokine balance required for protection against <italic>M. tuberculosis.</italic> However, as association between the macrophage activating CCL2 and the T cell activation IFN&#x003b3; and CXCL9 was only found in LNTB patients. When LPS-induced responses were investigated, there appeared to be no association between CCL2 and CXCL9 in limited disease (PTB and LNTB), but a correlation between these two chemokines was present in severe extrapulmonary TB. It is possible that in severe extrapulmonary disease where there is an overall reduction in IFN&#x003b3; possibly due to T cell anergy, CXCL9 secretion may lead to increased macrophage recruitment and inflammation, the lack of association between the chemokines and T cell regulation may result in progressive disease related pathology in the host. Overall, this work proposes differential chemokine regulation in limited and severe tuberculosis infections which may explain subsequent pathophysiological changes in the host. Further investigations into the mechanisms responsible for the control of macrophage activation in different disease states may further explain this phenomenon.</p></sec><sec sec-type="materials|methods" id="s4"><title>Materials and Methods</title><sec id="s4a"><title>Ethics statement</title><p>This study was conducted according to the principles expressed in the Declaration of Helsinki. The study was approved by the Institutional Review Board of Aga Khan University hospitals. All patients provided written informed consent for the collection of samples and subsequent analysis.</p></sec><sec id="s4b"><title>Subject selection</title><p>Seventy six patients were recruited from the Aga Khan University Hospital and Medical College (AKUH) and Masoomeen Hospital, Karachi. All study subjects were examined and evaluated by infectious diseases consultants. Patients were newly diagnosed or had taken less than 7 days of anti-tuberculous therapy (ATT). Patients with significant co-morbid conditions including diabetes mellitus, chronic renal failure, chronic liver disease, patients on high dose corticosteroid therapy were excluded to assure relatively unmodulated immunological parameters. All patients were tested and found to be HIV negative.</p><p>Patients with pulmonary TB (PTB, n&#x0200a;&#x0003d;&#x0200a;30) were diagnosed by clinical examination, chest X-ray, sputum acid fast bacillus (AFB) Zeihl Neelson staining, AFB culture and/ or clinical response to treatment (along with fever, cough and weight loss). All PTB patients had findings consistent with active TB as evaluated by one of the consulting physicians. Fifteen patients were found to have a positive AFB smear microscopy. Nine PTB patients had an AFB negative smear, but showed a favourable clinical response to ATT. Patients were diagnosed as having minimal, moderate or advanced pulmonary tuberculosis using a modified classification of the National Tuberculosis Association of the USA based on extent of lung tissue involvement <xref ref-type="bibr" rid="pone.0005158-Crofton1">&#x0005b;44&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005158-Hussain3">&#x0005b;45&#x0005d;</xref>. Of the PTB patients 6 had minimal, while 24 had moderate disease.</p><p>Diagnosis of TB lymphadenitis, spinal, abdominal and genitourinary TB was based on histopathological findings of chronic granulomatous inflammation with caseous necrosis, AFB staining and culture and supportive radiological evidence on CT or MRI. Diagnosis of meningeal TB was based on CSF biochemical findings, supported by AFB culture and findings on contrast-enhanced CT and/or MRI. Pleural TB was diagnosed on the basis of pleural fluid biochemical findings, AFB culture, histopathological findings on pleural biopsy and supportive radiological evidence on X-rays and/or contrast-enhanced CT scan</p><p>Patients with extrapulmonary TB (Epul-TB) were divided into two groups according to the WHO ranking of diseases severity based on bacillary load, extent of disease and anatomical site <xref ref-type="bibr" rid="pone.0005158-WHO1">&#x0005b;28&#x0005d;</xref>. Epul-TB patients were subsequently classified into less severe (LNTB) or severe (SevTB) disease. Of the 24 patients with LNTB, 23 had lymphadenitis and 1 had genitourinary TB. All LNTB patients were confirmed on histological findings consistent with tuberculosis. Twenty two patients had SevTB and their diagnostic criteria are provided in <xref ref-type="table" rid="pone-0005158-t002">Table 2</xref>.</p><p>BCG-vaccinated asymptomatic healthy volunteers who were staff at AKU with no known exposure to TB were used as endemic controls (Ecs). All volunteers had a normal chest X-Ray. Tuberculin skin testing (TST) was assessed by administering five tuberculin units on the volar surface of the right arm subcutaneously, and read by a single reader at 48 h. An induration of &#x02265;10 mm was used as a cutoff for positive responses and TST&#x02212; (n&#x0200a;&#x0003d;&#x0200a;17) Ecs were included in the study.</p></sec><sec id="s4c"><title>Reagents</title><p>Recombinant antigens ESAT6 and CFP10 were provided through the TB Vaccine Testing and Research Materials Contract, NIH, NIAID NO1-A1-40091, awarded to Colorado State University, USA.</p></sec><sec id="s4d"><title>Whole blood assay</title><p>Venous blood was diluted 1&#x02236;10 in RPMI-1640 medium and 200 &#x000b5;l set up per well in a 96 well tissue culture plate as described previously <xref ref-type="bibr" rid="pone.0005158-Hussain1">&#x0005b;29&#x0005d;</xref>. Whole blood cells were stimulated with recombinant antigens ESAT-6 (5 &#x000b5;g/ml) and CFP-10 (5 &#x000b5;g/ml) and cultured for up to 5 days. All samples were set up in replicates. Supernatants were collected at 2 and 5 day post-stimulation for cytokine and chemokine measurements. Samples were centrifuged to collect any cellular debris, aliquoted and stored at &#x02013;70 C until tested. Cytokines were measured at both 2 and 5 days post-stimulation. We have presented IFN&#x003b3; responses from whole blood cells at 5 day of culture to focus on T cell responses <xref ref-type="bibr" rid="pone.0005158-Black1">&#x0005b;21&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005158-Hussain1">&#x0005b;29&#x0005d;</xref>. IL10 increased only marginally from 2 to 5 day post-stimulation and there was no significant increase between the two times studied (data not shown). Therefore, we have further analyzed IL10 responses at 2 day post-stimulation. CCL2 and CXCL9 were optimally measured at 2 days post-stimulation.</p></sec><sec id="s4e"><title>ELISA for IFN&#x003b3;, IL-10 and CXCL9</title><p>IFN&#x003b3; and IL-10 was detected in cellular supernatants by using standards and ELISA reagents obtained from Endogen (Rockford, IL, USA). Cytokines were measured using a sandwich ELISA technique according to the manufacturer&#x02019;s instructions and as reported previously <xref ref-type="bibr" rid="pone.0005158-Hasan1">&#x0005b;30&#x0005d;</xref>. Recombinant human cytokine was used to obtain a dose response curve with a range of detection from 3.9&#x02013;1000 pg/ml. All experimental samples were tested in duplicate.</p><p>CXCL9 and CCL2 standards and monoclonal antibody pairs for capture and detection were obtained from R&#x00026;D Systems (Abingdon, UK). All measurements were carried out according to the manufacturer&#x02019;s recommendations and as described previously <xref ref-type="bibr" rid="pone.0005158-Hasan1">&#x0005b;30&#x0005d;</xref>. Recombinant human cytokine was used to obtain a dose response curve with a range of detection from 6.25&#x02013;500 pg/ml for CXCL9 and 6.25&#x02013;1000 pg/ml for CCL2.</p></sec><sec id="s4f"><title>Statistical analysis</title><p>Data is represented by box blots illustrating 25<sup>th</sup> and 75<sup>th</sup> quartiles with the median shown as a horizontal bar. Non-parametric statistical analysis was performed using Kruskal-Wallis and Mann-Whitney U tests as required. P values&#x02264;0.05 were considered to be statistically significant. Spearman&#x02019;s Rank Correlation was also performed, all using the Statistical Package for Social Sciences software (SPSS).</p></sec></sec></body><back><ack><p>Thanks for technical assistance to Maqboola Dojki, Rouknuddin Ali and Seema Jamil. Thanks for help with patient recruitment to Drs. Darshan Lal, Mustafa Wardug and Ghaffar Dawood.</p></ack><ref-list><title>References</title><ref id="pone.0005158-BoneciniAlmeida1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bonecini-Almeida</surname><given-names>MG</given-names></name><name><surname>Ho</surname><given-names>JL</given-names></name><name><surname>Boechat</surname><given-names>N</given-names></name><name><surname>Huard</surname><given-names>RC</given-names></name><name><surname>Chitale</surname><given-names>S</given-names></name><etal/></person-group><year>2004</year><article-title>Down-modulation of lung immune responses by interleukin-10 and transforming growth factor &#x003b2; (TGF-&#x003b2;) and analysis of TGF-&#x003b2; receptors I and II in active tuberculosis.</article-title><source>Infect Immun</source><volume>72</volume><fpage>2628</fpage><lpage>2634</lpage><pub-id pub-id-type="pmid">15102771</pub-id></citation></ref><ref id="pone.0005158-MendezSamperio1"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mendez-Samperio</surname><given-names>P</given-names></name><name><surname>Garcia</surname><given-names>E</given-names></name><name><surname>Vazquez</surname><given-names>A</given-names></name><name><surname>Palma</surname><given-names>J</given-names></name></person-group><year>2002</year><article-title>Regulation of interleukin-8 by interleukin-10 and transforming growth factor &#x003b2; in human monocytes infected with <italic>Mycobacterium bovis</italic>.</article-title><source>Clin Diag Lab Immunol</source><volume>9</volume><fpage>802</fpage><lpage>807</lpage></citation></ref><ref id="pone.0005158-Murray1"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>PJ</given-names></name><name><surname>Young</surname><given-names>RA</given-names></name></person-group><year>1999</year><article-title>Increased antimycobacterial immunity in interleukin-10 deficient mice.</article-title><source>Infect Immun</source><volume>67</volume><fpage>3087</fpage><lpage>3095</lpage><pub-id pub-id-type="pmid">10338525</pub-id></citation></ref><ref id="pone.0005158-Collins1"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>HL</given-names></name><name><surname>Kaufmann</surname><given-names>SHE</given-names></name></person-group><year>2001</year><article-title>The many faces of host responses to tuberculosis.</article-title><source>Immunol</source><volume>103</volume><fpage>1</fpage><lpage>9</lpage></citation></ref><ref id="pone.0005158-Ulrichs1"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ulrichs</surname><given-names>T</given-names></name><name><surname>Kosmiadi</surname><given-names>GA</given-names></name><name><surname>J&#x000f6;rg</surname><given-names>S</given-names></name><name><surname>Pradl</surname><given-names>L</given-names></name><name><surname>Titukhina</surname><given-names>M</given-names></name><etal/></person-group><year>2005</year><article-title>Differential organization of the local immune response in patients with active cavitary tuberculosis or with nonprogressive tuberculosis.</article-title><source>The Journal of Infectious Disease</source><volume>192</volume><fpage>89</fpage><lpage>97</lpage></citation></ref><ref id="pone.0005158-Algood1"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Algood</surname><given-names>HMS</given-names></name><name><surname>Chan</surname><given-names>J</given-names></name><name><surname>Flynn</surname><given-names>JL</given-names></name></person-group><year>2003</year><article-title>Chemokines and tuberculosis.</article-title><source>Cyt Growth Fact Rev</source><volume>14</volume><fpage>467</fpage><lpage>477</lpage></citation></ref><ref id="pone.0005158-Flynn1"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Flynn</surname><given-names>JL</given-names></name><name><surname>Ernst</surname><given-names>JD</given-names></name></person-group><year>2000</year><article-title>Immune responses in tuberculosis.</article-title><source>Curr Opin Immunol</source><volume>12</volume><fpage>432</fpage><lpage>436</lpage><pub-id pub-id-type="pmid">10899019</pub-id></citation></ref><ref id="pone.0005158-Scott1"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>HM</given-names></name><name><surname>Flynn</surname><given-names>JL</given-names></name></person-group><year>2002</year><article-title><italic>Mycobacterium tuberculosis</italic> in chemokine receptor 2-deficient mice: Influence of dose on disease progression.</article-title><source>Infect Immun</source><volume>70</volume><fpage>5946</fpage><lpage>5954</lpage><pub-id pub-id-type="pmid">12379669</pub-id></citation></ref><ref id="pone.0005158-Whiting1"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Whiting</surname><given-names>D</given-names></name><name><surname>Hsieh</surname><given-names>G</given-names></name><name><surname>Yun</surname><given-names>JJ</given-names></name><name><surname>Banerji</surname><given-names>A</given-names></name><name><surname>Yao</surname><given-names>W</given-names></name><etal/></person-group><year>2004</year><article-title>Chemokine monokine induced by IFN-gamma/CXC chemokine ligand 9 stimulates T lymphocyte proliferation and effector cytokine production.</article-title><source>J Immunol</source><volume>172</volume><fpage>7417</fpage><lpage>7424</lpage><pub-id pub-id-type="pmid">15187119</pub-id></citation></ref><ref id="pone.0005158-Brice1"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brice</surname><given-names>GT</given-names></name><name><surname>Graber</surname><given-names>JL</given-names></name><name><surname>Hoffman</surname><given-names>SL</given-names></name><name><surname>Doolan</surname><given-names>DL</given-names></name></person-group><year>2001</year><article-title>Expression of the chemokine MIG is a sensitive and predictive marker for antigen-specific, genetically restricted IFN-gamma production and IFN-gamma-secreting cells.</article-title><source>J Immunol Methods</source><volume>257</volume><fpage>55</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">11687239</pub-id></citation></ref><ref id="pone.0005158-Berthet1"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berthet</surname><given-names>FX</given-names></name><name><surname>Rasmussen</surname><given-names>PB</given-names></name><name><surname>Rosenkrands</surname><given-names>I</given-names></name><name><surname>Andersen</surname><given-names>P</given-names></name><name><surname>Gicquel</surname><given-names>B</given-names></name></person-group><year>1998</year><article-title>Mycobacterium tuberculosis operon encoding ESAT6 and a novel low-molecular-mass culture filtrate protein (CFP-10).</article-title><source>Microbiol</source><volume>144</volume><fpage>195</fpage><lpage>203</lpage></citation></ref><ref id="pone.0005158-Harboe1"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harboe</surname><given-names>M</given-names></name><name><surname>Oettinger</surname><given-names>T</given-names></name><name><surname>Wiker</surname><given-names>HG</given-names></name><name><surname>Rosenkrands</surname><given-names>I</given-names></name><name><surname>Andersen</surname><given-names>P</given-names></name></person-group><year>1996</year><article-title>Evidence for occurrence of the ESAT6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis for its absence in Mycobacterium novis BCG.</article-title><source>Infect Immun</source><volume>64</volume><fpage>16</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">8557334</pub-id></citation></ref><ref id="pone.0005158-Ravn1"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ravn</surname><given-names>P</given-names></name><name><surname>Munk</surname><given-names>ME</given-names></name><name><surname>Andersen</surname><given-names>AB</given-names></name><name><surname>Lundgren</surname><given-names>B</given-names></name><name><surname>Lundgren</surname><given-names>JD</given-names></name><etal/></person-group><year>2005</year><article-title>Prospective evaluation of a whole-blood test using Mycobacterium tuberculosis-specific antigens ESAT-6 and CFP-10 for diagnosis of active tuberculosis.</article-title><source>Clin Diagn Lab Immunol</source><volume>12</volume><fpage>491</fpage><lpage>496</lpage><pub-id pub-id-type="pmid">15817755</pub-id></citation></ref><ref id="pone.0005158-Ulrichs2"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ulrichs</surname><given-names>T</given-names></name><name><surname>Anding</surname><given-names>P</given-names></name><name><surname>Porcelli</surname><given-names>S</given-names></name><name><surname>Kaufmann</surname><given-names>SHE</given-names></name><name><surname>Munk</surname><given-names>ME</given-names></name></person-group><year>2000</year><article-title>Increased numbers of ESAT6 and purified protein derivative-specific gamma interferon-producing cells in subclinical and active tuberculosis infection.</article-title><source>Infect Immun</source><volume>68</volume><fpage>6073</fpage><lpage>6076</lpage><pub-id pub-id-type="pmid">10992526</pub-id></citation></ref><ref id="pone.0005158-Kobashi1"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kobashi</surname><given-names>Y</given-names></name><name><surname>Mouri</surname><given-names>K</given-names></name><name><surname>Yagi</surname><given-names>S</given-names></name><name><surname>Obase</surname><given-names>Y</given-names></name><name><surname>Miyashita</surname><given-names>N</given-names></name><etal/></person-group><year>2008</year><article-title>Clinical utility of the QuantiFERON TB-2G test for elderly patients with active tuberculosis.</article-title><source>Chest</source><volume>7</volume><fpage>1995</fpage></citation></ref><ref id="pone.0005158-Britton1"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Britton</surname><given-names>WJ</given-names></name><name><surname>Gilbert</surname><given-names>GL</given-names></name><name><surname>Wheatley</surname><given-names>J</given-names></name><name><surname>Leslie</surname><given-names>D</given-names></name><name><surname>Rothel</surname><given-names>JS</given-names></name><etal/></person-group><year>2005</year><article-title>Sensitivity of human gamma interferon assay and tuberculin skin testing for detecting infection with Mycobacterium tuberculosis in patients with culture positive tuberculosis.</article-title><source>Tuberculosis</source><volume>85</volume><fpage>137</fpage><lpage>145</lpage><pub-id pub-id-type="pmid">15850752</pub-id></citation></ref><ref id="pone.0005158-Abramo1"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abramo</surname><given-names>C</given-names></name><name><surname>Meijgaarden</surname><given-names>K</given-names></name><name><surname>Garcia</surname><given-names>D</given-names></name><name><surname>Franken</surname><given-names>K</given-names></name><name><surname>Klein</surname><given-names>M</given-names></name><etal/></person-group><year>2006</year><article-title>Monokine induced by interferon gamma and IFN-gamma response to a fusion protein of Mycobacterium tuberculosis ESAT-6 and CFP-10 in Brazilian tuberculosis patients.</article-title><source>Microbes Infect</source><volume>8</volume><fpage>45</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">16269263</pub-id></citation></ref><ref id="pone.0005158-Brock1"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brock</surname><given-names>I</given-names></name><name><surname>Munck</surname><given-names>ME</given-names></name><name><surname>Jensen</surname><given-names>AK</given-names></name><name><surname>Anderson</surname><given-names>P</given-names></name></person-group><year>2001</year><article-title>Performance of whole blood IFN-&#x003b3; test for tuberculosis diagnosis based on PPD or the specif antigens ESAT-6 and CFP-10.</article-title><source>Int J Lung Tuberc Dis</source><volume>5</volume><fpage>462</fpage><lpage>467</lpage></citation></ref><ref id="pone.0005158-Ulrichs3"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ulrichs</surname><given-names>T</given-names></name><name><surname>Andind</surname><given-names>P</given-names></name><name><surname>Kaufmann</surname><given-names>SHE</given-names></name><name><surname>Munk</surname><given-names>ME</given-names></name></person-group><year>2000</year><article-title>Numbers of IFN-&#x003b3; producing cells against ESAT-6 increase in tuberculosis patients during chemotherapy.</article-title><source>Int J Lung Tuberc Dis</source><volume>12</volume><fpage>1181</fpage><lpage>1183</lpage></citation></ref><ref id="pone.0005158-Weir1"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weir</surname><given-names>RE</given-names></name><name><surname>Fine</surname><given-names>PE</given-names></name><name><surname>Floyd</surname><given-names>S</given-names></name><name><surname>Stenson</surname><given-names>S</given-names></name><name><surname>Stanley</surname><given-names>C</given-names></name><etal/></person-group><year>2008</year><article-title>Comparison of IFN-&#x003b3; responses to mycobacterial antigens as markers of response to BCG vaccination.</article-title><source>Tuberculosis</source><volume>88</volume><fpage>31</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">18277396</pub-id></citation></ref><ref id="pone.0005158-Black1"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Black</surname><given-names>GF</given-names></name><name><surname>Weir</surname><given-names>RE</given-names></name><name><surname>Chaguluka</surname><given-names>SD</given-names></name><name><surname>Warndorff</surname><given-names>D</given-names></name><name><surname>Crampin</surname><given-names>AC</given-names></name><etal/></person-group><year>2003</year><article-title>Gamma Interferon Responses Induced by a Panel of Recombinant and Purified Mycobacterial Antigens in Healthy, Non-<italic>Mycobacterium bovis</italic> BCG-Vaccinated Malawian Young Adults.</article-title><source>Clin Diagn Lab Immunol</source><volume>10</volume><fpage>602</fpage><lpage>611</lpage><pub-id pub-id-type="pmid">12853392</pub-id></citation></ref><ref id="pone.0005158-Chee1"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chee</surname><given-names>CBE</given-names></name><name><surname>Gan</surname><given-names>SH</given-names></name><name><surname>KhinMar</surname><given-names>KW</given-names></name><name><surname>Barkham</surname><given-names>TM</given-names></name><name><surname>Koh</surname><given-names>CK</given-names></name><etal/></person-group><year>2008</year><article-title>Sensitivity comparison of two commercial interferon-gamma release assays in pulmonary tuberculosis.</article-title><source>J Clin Microbiol</source></citation></ref><ref id="pone.0005158-Mazurek1"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mazurek</surname><given-names>GH</given-names></name><name><surname>Weis</surname><given-names>SE</given-names></name><name><surname>Moonan</surname><given-names>PK</given-names></name><name><surname>Daley</surname><given-names>CL</given-names></name><name><surname>Bernardo</surname><given-names>J</given-names></name><etal/></person-group><year>2007</year><article-title>Prospective comparison of the tuberculin skin test and 2 whole blood interferon-&#x003b3; release assays in persons with suspected tuberculosis.</article-title><source>CID</source><volume>45</volume><fpage>837</fpage><lpage>845</lpage></citation></ref><ref id="pone.0005158-Demissie1"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Demissie</surname><given-names>A</given-names></name><name><surname>Wassie</surname><given-names>L</given-names></name><name><surname>Abebe</surname><given-names>M</given-names></name><name><surname>Aseffa</surname><given-names>A</given-names></name><name><surname>Rook</surname><given-names>G</given-names></name><etal/></person-group><year>2006</year><article-title>The 6-kilodalton early secreted antigenic target-responsive, asymptomatic contacts of tuberculosis patients express elevated levels of interleukin-4 and reduced levels of gamma interferon.</article-title><source>Infect Immun</source><volume>74</volume><fpage>2817</fpage><lpage>2822</lpage><pub-id pub-id-type="pmid">16622219</pub-id></citation></ref><ref id="pone.0005158-Ruhwald1"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ruhwald</surname><given-names>M</given-names></name><name><surname>Bodmer</surname><given-names>T</given-names></name><name><surname>Maier</surname><given-names>C</given-names></name><name><surname>Jepsen</surname><given-names>M</given-names></name><name><surname>Haaland</surname><given-names>MB</given-names></name><etal/></person-group><year>2008</year><article-title>Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis.</article-title><source>Eur Respir J</source><volume>32</volume><fpage>1607</fpage><lpage>1615</lpage><pub-id pub-id-type="pmid">18684849</pub-id></citation></ref><ref id="pone.0005158-Cagatay1"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cagatay</surname><given-names>AA</given-names></name><name><surname>Caliskan</surname><given-names>Y</given-names></name><name><surname>Aksoz</surname><given-names>S</given-names></name><name><surname>Gulec</surname><given-names>L</given-names></name><name><surname>Kucukoglu</surname><given-names>S</given-names></name><etal/></person-group><year>2004</year><article-title>Extrapulmonary tuberculosis in immunocompetent adults.</article-title><source>Scan J Infect Dis</source><volume>36</volume><fpage>799</fpage><lpage>806</lpage></citation></ref><ref id="pone.0005158-Ebdrup1"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ebdrup</surname><given-names>L</given-names></name><name><surname>Storgaard</surname><given-names>M</given-names></name><name><surname>Jensen-Fangel</surname><given-names>S</given-names></name><name><surname>Obel</surname><given-names>N</given-names></name></person-group><year>2003</year><article-title>Ten years of extrapulmonary tuberculosis in a Danish university clinic.</article-title><source>Scan J Infect Dis</source><volume>35</volume><fpage>244</fpage><lpage>246</lpage></citation></ref><ref id="pone.0005158-WHO1"><label>28</label><citation citation-type="journal"><collab>WHO</collab><year>2008</year><article-title>Country Profile Pakistan</article-title><fpage>133</fpage><lpage>136</lpage></citation></ref><ref id="pone.0005158-Hussain1"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hussain</surname><given-names>R</given-names></name><name><surname>Kaleem</surname><given-names>A</given-names></name><name><surname>Shahid</surname><given-names>F</given-names></name><name><surname>Dojki</surname><given-names>M</given-names></name><name><surname>Jamil</surname><given-names>B</given-names></name><etal/></person-group><year>2002</year><article-title>Cytokine profiles using whole-blood assays can discriminate between tuberculosis patients and healthy endemic controls in a BCG-vaccinated population.</article-title><source>J Immunol Methods</source><volume>264</volume><fpage>95</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">12191514</pub-id></citation></ref><ref id="pone.0005158-Hasan1"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hasan</surname><given-names>Z</given-names></name><name><surname>Zaidi</surname><given-names>I</given-names></name><name><surname>Jamil</surname><given-names>B</given-names></name><name><surname>Khan</surname><given-names>MA</given-names></name><name><surname>Kanji</surname><given-names>A</given-names></name><etal/></person-group><year>2005</year><article-title>Elevated <italic>ex vivo</italic> monocyte chemotactic protein-1 (CCL2) in pulmonary as compared with extra-pulmonary tuberculosis.</article-title><source>BMC Immunol</source><volume>6</volume><fpage>14</fpage><pub-id pub-id-type="pmid">16001981</pub-id></citation></ref><ref id="pone.0005158-Hussain2"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hussain</surname><given-names>R</given-names></name><name><surname>Talat</surname><given-names>N</given-names></name><name><surname>Shahid</surname><given-names>F</given-names></name><name><surname>Dawood</surname><given-names>G</given-names></name></person-group><year>2007</year><article-title>Longitudinal tracking of cytokine after acute exposure to tuberculosis: association of distinct cytokine patterns with protection and disease development.</article-title><source>Clin Vac Immunol</source><volume>14</volume><fpage>1578</fpage><lpage>1586</lpage></citation></ref><ref id="pone.0005158-Jamil1"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jamil</surname><given-names>B</given-names></name><name><surname>Shahid</surname><given-names>F</given-names></name><name><surname>Hasan</surname><given-names>Z</given-names></name><name><surname>Nasir</surname><given-names>N</given-names></name><name><surname>Razzaki</surname><given-names>T</given-names></name><etal/></person-group><year>2007</year><article-title>Interferon &#x003b3;:IL10 ratio defines the severity of disease in pulmonary and extra-pulmonary tuberculosis.</article-title><source>Tuberculosis</source><volume>87</volume><fpage>279</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">17532265</pub-id></citation></ref><ref id="pone.0005158-Hasan2"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hasan</surname><given-names>Z</given-names></name><name><surname>Jamil</surname><given-names>B</given-names></name><name><surname>Khan</surname><given-names>J</given-names></name><name><surname>Ali</surname><given-names>R</given-names></name><name><surname>Khan</surname><given-names>MA</given-names></name><etal/></person-group><year>2009</year><article-title>Relationship between Circulating Levels of IFN&#x003b3;, IL10, CXCL9 and CCL2 in Pulmonary and Extrapulmonary Tuberculosis is Dependent on Disease Severity.</article-title><source>Scan J Immunol</source><volume>69</volume><fpage>259</fpage><lpage>267</lpage></citation></ref><ref id="pone.0005158-Weir2"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weir</surname><given-names>RE</given-names></name><name><surname>Black</surname><given-names>GF</given-names></name><name><surname>Dockrell</surname><given-names>HM</given-names></name><name><surname>Floyd</surname><given-names>S</given-names></name><name><surname>Fine</surname><given-names>PE</given-names></name></person-group><year>2004</year><article-title>Mycobacterial purified protein derivatives stimulate innate immunity: Malawians show enhaced tumor necrosis factor alpha, interleukin-1&#x003b2; (IL-1&#x003b2;), and IL10 responses compared to those of adolescents in the United Kingdom.</article-title><source>Infect Immun</source><volume>72</volume><fpage>1807</fpage><lpage>1811</lpage><pub-id pub-id-type="pmid">14977992</pub-id></citation></ref><ref id="pone.0005158-Hasan3"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hasan</surname><given-names>Z</given-names></name><name><surname>Jamil</surname><given-names>B</given-names></name><name><surname>Zaidi</surname><given-names>I</given-names></name><name><surname>Zafar</surname><given-names>S</given-names></name><name><surname>Khan</surname><given-names>AA</given-names></name><etal/></person-group><year>2006</year><article-title>Elevated serum CCL2 concomitant with a reduced Mycobacterium-induced response leads to disease dissemination in leprosy.</article-title><source>Scan J Immunol</source><volume>63</volume><fpage>241</fpage><lpage>247</lpage></citation></ref><ref id="pone.0005158-Walrath1"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Walrath</surname><given-names>J</given-names></name><name><surname>Zukowski</surname><given-names>L</given-names></name><name><surname>Keywiak</surname><given-names>A</given-names></name><name><surname>Silver</surname><given-names>RF</given-names></name></person-group><year>2005</year><article-title>Resident Th1-Like Effector Memory Cells in Pulmonary Recall Responses to <italic>Mycobacterium tuberculosis</italic>.</article-title><source>American Journal of Respiratory Cell and Molecular Biology</source><volume>33</volume><fpage>48</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">15778493</pub-id></citation></ref><ref id="pone.0005158-Pathan1"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pathan</surname><given-names>AA</given-names></name><name><surname>Wilkinson</surname><given-names>KA</given-names></name><name><surname>Klenerman</surname><given-names>P</given-names></name><name><surname>McShane</surname><given-names>H</given-names></name><name><surname>Davidson</surname><given-names>RN</given-names></name><etal/></person-group><year>2001</year><article-title>Direct ex vivo analysis of antigen-specific IFN&#x003b3; secreting CD4 T cells in <italic>Mycobacterium tuberculosis</italic>-infected individuals: associations with clinical disease state and effect of treatment.</article-title><source>J Immunol</source><volume>167</volume><fpage>5217</fpage><lpage>5225</lpage><pub-id pub-id-type="pmid">11673535</pub-id></citation></ref><ref id="pone.0005158-Dlugovitzky1"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dlugovitzky</surname><given-names>D</given-names></name><name><surname>Torres-Morales</surname><given-names>A</given-names></name><name><surname>Rateni</surname><given-names>L</given-names></name><name><surname>Farroni</surname><given-names>MA</given-names></name><name><surname>Largacha</surname><given-names>C</given-names></name><etal/></person-group><year>1997</year><article-title>Circulating profile of Th1 and Th2 cytokines in tuberculosis patients with different degrees of pulmonary involvement.</article-title><source>FEMS Immunol Med Microbiol</source><volume>18</volume><fpage>203</fpage><lpage>207</lpage><pub-id pub-id-type="pmid">9271171</pub-id></citation></ref><ref id="pone.0005158-Sharma1"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>SK</given-names></name><name><surname>Mitra</surname><given-names>DK</given-names></name><name><surname>Balamurugan</surname><given-names>A</given-names></name><name><surname>Pandey</surname><given-names>RM</given-names></name><name><surname>Mehra</surname><given-names>NK</given-names></name></person-group><year>2002</year><article-title>Cytokine polarization in miliary and pleural tuberculosis.</article-title><source>J Clin Immunol</source><volume>22</volume><fpage>345</fpage><lpage>352</lpage><pub-id pub-id-type="pmid">12462334</pub-id></citation></ref><ref id="pone.0005158-Sahiratmadja1"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sahiratmadja</surname><given-names>E</given-names></name><name><surname>Alisjahbana</surname><given-names>B</given-names></name><name><surname>Boer</surname><given-names>TB</given-names></name><name><surname>Adnan</surname><given-names>I</given-names></name><name><surname>Maya</surname><given-names>A</given-names></name><etal/></person-group><year>2007</year><article-title>Dynamic changes in pro- and anti-inflammatory cytokine profiles and gamma interferon receptor signaling integrity correlate with tuberculosis disease activity and response to curative treatment.</article-title><source>Infect Immun</source><volume>75</volume><fpage>820</fpage><lpage>829</lpage><pub-id pub-id-type="pmid">17145950</pub-id></citation></ref><ref id="pone.0005158-GonzalezJuarrero1"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez-Juarrero</surname><given-names>M</given-names></name><name><surname>Kingry</surname><given-names>LC</given-names></name><name><surname>Ordway</surname><given-names>DJ</given-names></name><name><surname>Henao-Tamayo</surname><given-names>M</given-names></name><name><surname>Harton</surname><given-names>M</given-names></name><etal/></person-group><year>2008</year><article-title>Immune response of Mycobacterium tuberculosis and identification of molecular markers of disease.</article-title><source>Am J Respir Cell Mol Biol Sep</source></citation></ref><ref id="pone.0005158-Mastroianni1"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mastroianni</surname><given-names>CM</given-names></name><name><surname>Lancella</surname><given-names>L</given-names></name><name><surname>Mengoni</surname><given-names>F</given-names></name><name><surname>Lichtner</surname><given-names>M</given-names></name><name><surname>Santopadre</surname><given-names>P</given-names></name><etal/></person-group><year>1998</year><article-title>Chemokine profiles in the cerebrospinal fluid (CSF) during the course of pyogenic and tuberculous meningitis.</article-title><source>Clin Exp Immunol</source><volume>114</volume><fpage>210</fpage><lpage>214</lpage><pub-id pub-id-type="pmid">9822278</pub-id></citation></ref><ref id="pone.0005158-Thwaites1"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thwaites</surname><given-names>GE</given-names></name><name><surname>Simmons</surname><given-names>CP</given-names></name><name><surname>Quyen</surname><given-names>NTH</given-names></name><name><surname>Chau</surname><given-names>TTH</given-names></name><name><surname>Mai</surname><given-names>PP</given-names></name><etal/></person-group><year>2003</year><article-title>Pathophysiology and prognosis in Vietnamese adults with tuberculous meningitis.</article-title><source>J Infect Dis</source><volume>188</volume><fpage>1105</fpage><lpage>1115</lpage><pub-id pub-id-type="pmid">14551879</pub-id></citation></ref><ref id="pone.0005158-Crofton1"><label>44</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Crofton</surname><given-names>J</given-names></name></person-group><year>1990</year><article-title>Clinical features of tuberculosis.</article-title><source>Crofton and Douglas Respiratory Diseases</source><publisher-loc>London</publisher-loc><publisher-name>Blackwell Scientific</publisher-name><fpage>395</fpage><lpage>421</lpage></citation></ref><ref id="pone.0005158-Hussain3"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hussain</surname><given-names>R</given-names></name><name><surname>Hasan</surname><given-names>R</given-names></name><name><surname>Khurshid</surname><given-names>M</given-names></name><name><surname>Sturm</surname><given-names>AW</given-names></name><name><surname>Ellner</surname><given-names>JJ</given-names></name><etal/></person-group><year>1996</year><article-title>Pulmonary tuberculosis in a BCG vaccinated area: Relationship of disease severity with immunological and hematological parameters and drug resistance patterns.</article-title><source>Southeast Asian J Trop Med Pub Health</source><volume>27</volume><fpage>1</fpage><lpage>6</lpage></citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This investigation received financial support from the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR). The project was partially supported by Research Grant from the Third World Academy of Sciences for the Developing World (TWAS). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.</p></fn></fn-group></back></article> 